Qiao Li, Rao Yifan, Zhu Keting, Rao Xiancai, Zhou Renjie
Department of Emergency, Xinqiao Hospital, Army Medical University, Chongqing, China.
Department of Microbiology, College of Basic Medical Sciences, Key Laboratory of Microbial Engineering Under the Educational Committee in Chongqing, Army Medical University, Chongqing, China.
Front Microbiol. 2021 Oct 8;12:729369. doi: 10.3389/fmicb.2021.729369. eCollection 2021.
Bacterial membrane vesicles (MVs) are produced by both Gram-positive and Gram-negative bacteria during growth and . MVs are nanoscale vesicular structures with diameters ranging from 20 to 400 nm. MVs incorporate bacterial lipids, proteins, and often nucleic acids, and can effectively stimulate host immune response against bacterial infections. As vaccine candidates and drug delivery systems, MVs possess high biosafety owing to the lack of self-replication ability. However, wild-type bacterial strains have poor MV yield, and MVs from the wild-type strains may be harmful due to the carriage of toxic components, such as lipopolysaccharides, hemolysins, enzymes, etc. In this review, we summarize the genetic modification of vesicle-producing bacteria to reduce MV toxicity, enhance vesicle immunogenicity, and increase vesicle production. The engineered MVs exhibit broad applications in vaccine designs, vaccine delivery vesicles, and drug delivery systems.
细菌膜泡(MVs)由革兰氏阳性菌和革兰氏阴性菌在生长过程中产生。MVs是直径为20至400纳米的纳米级囊泡结构。MVs包含细菌脂质、蛋白质,且常常含有核酸,并能有效刺激宿主针对细菌感染的免疫反应。作为候选疫苗和药物递送系统,MVs由于缺乏自我复制能力而具有较高的生物安全性。然而,野生型细菌菌株的MV产量较低,且来自野生型菌株的MVs可能因携带脂多糖、溶血素、酶等有毒成分而具有危害性。在本综述中,我们总结了对产生膜泡的细菌进行基因改造,以降低MV毒性、增强膜泡免疫原性并提高膜泡产量。工程化的MVs在疫苗设计、疫苗递送囊泡和药物递送系统中具有广泛应用。